| Autor: |
S, Patel, S, Freedman, L, Chapman K, F, Emms, E, Fletcher A, M, Knowles, R, Marwood, G, Mcallister, J, Myers, N, Curtis, J, Kulagowski J, D, Leeson P, M, Ridgill, M, Graham, S, Matheson, D, Rathbone, P, Watt A, J, Bristow L, M, Rupniak N, E, Baskin, J, Lynch J, I, Ragan C |
| Zdroj: |
The Journal of Pharmacology and Experimental Therapeutics; November 1997, Vol. 283 Issue: 2 p636-47, 12p |
| Abstrakt: |
L-745,870,(3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1H- pyrollo[2,3-b] pyridine, was identified as a selective dopamine D4 receptor antagonist with excellent oral bioavailability and brain penetration. L-745,870 displaced specific binding of 0.2 nM [3H] spiperone to cloned human dopamine D4 receptors with a binding affinity (Ki) of 0. 43 nM which was 5- and 20-fold higher than that of the standard antipsychotics haloperidol and clozapine, respectively. L-745,870 exhibited high selectivity for the dopamine D4 receptor (>2000 fold) compared to other dopamine receptor subtypes and had moderate affinity for 5HT2, sigma and alpha adrenergic receptors(IC50 < 300 nM). In vitro, L-745,870 (0.1-1 microM) exhibited D4 receptor antagonist activity, reversing dopamine (1 microM) mediated 1) inhibition of adenylate cyclase in hD4HEK and hD4CHO cells; 2) stimulation of [35S] GTPgammaS binding and 3) stimulation of extracellular acidification rate, but did not exhibit any significant intrinsic activity in these assays. Although standard antipsychotics increase dopamine metabolism or plasma prolactin levels in rodents, L-745,870 (
|
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
